The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index; 2 of the 13 sources its claims cite were checked for support.
Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.”
Open accessAbstract
Thank you providing the opportunity to reply to the Comment on our recent paper.[...]
Overview
CoChat Summary
TL;DR
Burckhardt replies to Strom and Andreasen's Comment on Neiser et al. (2016), arguing that the ELISA study was never intended to be extrapolated to the clinical setting and defending its use of a new antibody and blinded samples. The reply also contends that recent reports of higher hypersensitivity rates with dextran-based intravenous iron support the value of such in vitro data.
Key findings
- The 2016 experiments were triggered by earlier criticism of the 2011 immunodiffusion work; they used a new antibody (produced by GenScript) and a different technique (ELISA), with blinded samples run by GenScript to avoid bias.
- The author states that neither Neiser et al. [1] nor prior publications [3,8] made any claim about the clinical relevance of the experiments, and that the mechanism of intravenous iron-induced hypersensitivity reactions "has not been elucidated yet."
- The reply cites recent studies [9–12] concluding that hypersensitivity reaction frequency is higher with dextran-based intravenous iron preparations (including newer ones) than with non-dextran products, noting these disagree with the paper cited by Strom and Andreasen [6].
- The data are said to demonstrate that Isomaltoside 1000 reacts with anti-dextran antibodies when bound to a polynuclear iron core, contrary to Crichton et al.'s speculation that Dextran 1 (not Isomaltoside 1000) does so; the author argues this is important for designing new intravenous iron preparations.
Methods
- This is a reply letter, not a primary research report; it presents no new experimental data or analyses of its own.
- It describes the design of the original study under discussion: ELISA with a new anti-dextran antibody and blinded samples, chosen to address prior methodological criticism of the reverse single radial immunodiffusion assay.
Limitations
- Stated in the paper: the mechanism(s) of intravenous iron-induced hypersensitivity reactions remain unelucidated and more studies are needed; the low incidence of these reactions and lack of understanding of their triggers are noted as reasons any additional data are valuable.
- Evident from the text: as a reply to a Comment, the piece offers argumentation and references rather than new experiments, so its claims rest on the original 2016 study and cited literature; the author also notes the study was not designed to be extrapolated to the clinical setting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 2 Not valid · 4 Not checked · 4 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our data demonstrate that this is the case for Isomaltoside 1000.”
§ Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.” > To the Editor:
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“In response to Strom and Andreasen, I would like to state that, as clearly mentioned in the introduction, the experiments described in Neiser et al. [1] were triggered by the criticism [2] of our previous work published in 2011 [3].”
§ Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.” > To the Editor:
What the sources say
- Not checked yetcites [2] Ring, 2012, Letter to the Editor on the article “Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay”, Port. J. Nephrol. Hypertens.
- Not checked yetcites [3] Neiser, 2011, Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay, Port. J. Nephrol. Hypertens.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Notably, the rationale for the design of Iron isomaltoside 1000 was based on the “theoretically reduced anaphylactogenic potential” of the ligand [14,15].”
§ Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.” > To the Editor:
What the sources say
- Not checked yetcites [14] Kalra, 2011, Introducing iron isomaltoside 1000 (Monofer®)—Development rationale and clinical experience, NDT Plus
- Not checked yetcites [15] Jahn, 2011, A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications, Eur. J. Pharm. Biopharm. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nevertheless, despite the fact that carboxymaltose is a branched starch derivative, because of the extensive substitution (hydroxyethyl) in HES, the two compounds are not comparable.”
§ Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.” > To the Editor:
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the conclusion that a non-immunogenic carbohydrate bound to a polynuclear iron core may form multivalent immune complexes and react with antibodies is important and may be valuable for the design of new intravenous iron preparations.”
§ Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.” > To the Editor:
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
11 references still to check
A free account verifies the references that are still open.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 1
Citations
Cites
Jahn, M. R., Andreasen, H. B., Fütterer, S., Nawroth, T., Schünemann, V., Kolb, U., Hofmeister, W., Muñoz, M., Bock, K., Meldal, M., et al. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.03.016 · Cited by 256 · cited 1×
“Notably, the rationale for the design of Iron isomaltoside 1000 was based on the “theoretically reduced anaphylactogenic potential” of the ligand [14,15].”
BackgroundComparative risk of anaphylactic reactions associated With intravenous iron products
Wang, C., Graham, D. J., Kane, R. C., Xie, D., Wernecke, M., Levenson, M., MaCurdy, T. E., Houstoun, M., Ryan, Q., Wong, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.15572 · Cited by 219
Safety of intravenous iron formulations: facts and folklore.
Auerbach, M., & Macdougall, I. C. (2014) · PubMed · doi:10.2450/2014.0094-14 · Cited by 122
Bager, P., Hvas, C. L., & Dahlerup, J. F. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13189 · Cited by 75
Anaphylaxis due to hydroxyethyl-starch-reactive antibodies
Kreimeier, U., Christ, F., Kraft, D., Lauterjung, L., Niklas, M., Peter, K., & Meßmer, K. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92677-1 · Cited by 61
High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing?
Rodgers, G. M., Auerbach, M., Cella, D., Chertow, G. M., Coyne, D. W., Glaspy, J. A., & Henry, D. H. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008030255 · Cited by 56
Safety of intravenous iron use in chronic kidney disease
Kalra, P. A., & Bhandari, S. (2016) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000263 · Cited by 50
Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay
Neiser, S., Wilhelm, M., Schwarz, K., Funk, F., Geisser, P., & Burckhardt, S. (2011) · Cited by 24
Self-citationNeiser, S., Koskenkorva, T., Schwarz, K., Wilhelm, M., & Burckhardt, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071185 · Cited by 21
Self-citationIntroducing iron isomaltoside 1000 (Monofer(R))--development rationale and clinical experience
Kalra, P. A. (2011) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfr042 · Cited by 9
Research works printed but not linked: 1
- Ring, 2012, Letter to the Editor on the article “Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay”, Port. J. Nephrol. Hypertens., 26, 308
Cited by
Still being checked.
Metadata
- Authors
- Burckhardt, S.
- Affiliations
- Vifor Pharma (Switzerland) (CH)
- Corresponding author
- Burckhardt, Susanna
- ORCID
- Burckhardt, Susanna
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-01-10
- Volume
- 18
- Issue
- 1
- Pages
- 122
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5297756
- OpenAlex
- W2571170834
- Cited by
- 0
- References
- 12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- iron dextran, ELISA, drug safety assessment
- MeSH terms
- Dextrans, Enzyme-Linked Immunosorbent Assay, Humans, Iron, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.”. https://app.cochat.ai/papers/10.3390/ijms18010122
- The paper
- Burckhardt, S. (2017). Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.”. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18010122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.